Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.

Provided herein are methods for monitoring treatment for multiple sclerosis in a pregnant subject, and determining the efficacy of a treatment for multiple sclerosis in a pregnant subject. These methods include (a) extracting a drug from a dried blood spot (DBS) sample from a pregnant subject after a treatment for multiple sclerosis has been administered to the pregnant subject; (b) performing mass spectrometry on the extracted DBS sample; (c) determining a peak area ratio of the extracted DBS sample to an internal standard; and (d) identifying the administered treatment as being below the internal standard threshold if the plasma concentration of the treatment is less than 1 as compared to the internal standard ratio. Also provided herein are dried blood spot cards, and kits that include a dried blood spot card pre-treated with at least one internal standard.

The present disclosure provides systems and methods for measuring a property of a sample. In some embodiments, the system comprises a test strip for collecting the sample, and a diagnostic measuring device configured to receive the test strip and measure a concentration of an analyte in the sample received on the test strip. The diagnostic measuring device further comprises a processor programmed to execute an analyte correction for correcting a measurement of the sample due to one or more interferents, including hematocrit, by using a four-wire sense circuit to measure HCT true complex impedance. The complex HCT impedance is mapped to HCT percentage by empirical methods and can then be used to compensate the glucose measurement for a more accurate blood glucose result.

The invention principally relates to a method of detecting a disease agent in blood, comprising: (i) creating a sample infra-red spectrum representative of the blood, with one or more spectral components, each having a wavenumber and absorbance value; (ii) providing a reference database of spectral models, each model having one or more database spectral components of a wavenumber and an absorbance value, wherein the database spectral components identify disease agents; (iii) determining whether one or more database spectral components corresponds to one or more sample spectral components; and (iv) compiling a list of corresponding database components identified.

The present invention relates to a device and a method for analysing a sample comprising from 0.1 pg to 1 μg of analyte, and more specifically to a lateral flow device and a method for testing the presence of very low amounts of drugs or drug meta bolites in a sample. The present invention also relates to a method of dissolving a bodily fluid.

Methods and apparatus for providing data processing and control for use in a medical communication system are provided.

Provided are methods of determining prior radiation dose exposure levels for subjects, and kits therefor. Also provided are methods of treatment.

The present invention relates to containers for holding liquid samples. The containers may be useful for mixing a liquid sample or lysing cells in a liquid sample. The invention also relates to methods of using the containers of the invention.

This present invention relates generally to devices, systems, and methods for performing optical and electrochemical assays and, more particularly, to devices and systems having universal channel circuitry configured to perform optical and electrochemical assays, and methods of performing the optical and electrochemical assays using the universal channel circuitry. The universal channel circuitry is circuitry that has electronic switching capabilities such that any contact pin, and thus any sensor contact pad in a testing device, can be connected to one or more channels capable of taking on one or more measurement modes or configurations (e.g., an amperometric measurement mode or a current drive mode).

Systems and method that relate to improving levels, functions, and resistances related to chronic conditions by using lysine-based supplements are described. For example, a method of monitoring an analyte level may include administering a supplement that may include lysine, zinc, and vitamin C to a user. The method may also include monitoring an analyte level in a bio-sample before and after the supplement is administered.